Cargando…

SARS-CoV-2 Anti-Spike IgG Antibody and ACE2 Receptor Binding Inhibition Levels among Breakthrough Stage Veteran Patients

SARS-CoV-2 mRNA vaccines have been critical to curbing pandemic COVID-19; however, a major shortcoming has been the inability to assess levels of protection after vaccination. This study assessed serologic status of breakthrough infections in vaccinated patients at a Veterans Administration medical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chensue, Stephen W., Siler, Andrew F., Kim, Paul S., Dimcheff, Derek E., Daghfal, David J., Prostko, John, Frias, Edwin, Linder, Kathleen A., Schildhouse, Richard J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769865/ https://www.ncbi.nlm.nih.gov/pubmed/36409132 http://dx.doi.org/10.1128/spectrum.02747-22

Ejemplares similares

Effect of monoclonal antibody therapy on the endogenous SARS-CoV-2 antibody response
por: Kim, Paul S., et al.
Publicado: (2022)

Vaccine breakthrough infections in veterans hospitalized with coronavirus infectious disease-2019: A case series
por: Kim, Paul S., et al.
Publicado: (2022)

Seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection among Veterans Affairs healthcare system employees suggests higher risk of infection when exposed to SARS-CoV-2 outside the work environment
por: Dimcheff, Derek E., et al.
Publicado: (2020)

A comparative evaluation between the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™ SARS CoV-2 IgG assay
por: Batra, Rahul, et al.
Publicado: (2020)

IgG Against Human Betacoronavirus Spike Proteins Correlates With SARS-CoV-2 Anti-Spike IgG Responses and COVID-19 Disease Severity
por: Wang, Jiong, et al.
Publicado: (2022)

A case report of breakthrough infection with the SARS-CoV-2 delta variant and household transmission: Role of vaccination, anti-spike IgG and neutralizing activity
por: Moriyama, Yuki, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
por: Lei, Changhai, et al.
Publicado: (2020)

Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Coronavirus Disease 2019-Related Alterations of Total and Anti-Spike IgG Glycosylation in Relation to Age and Anti-Spike IgG Titer
por: Schwedler, Christian, et al.
Publicado: (2022)

IgG response to spike protein of SARS-CoV-2 in healthy individuals and potential of intravenous IgG as treatment for COVID-19
por: Wang, Gang, et al.
Publicado: (2022)

Th2 and Th17-Associated Immunopathology Following SARS-CoV-2 Breakthrough Infection in Spike-Vaccinated ACE2-humanized Mice
por: Zhang, Tianyi, et al.
Publicado: (2023)

Subclasses of allergen-specific IgG: Serum IgG2 and IgG3 levels are not predicted by IgG1/IgG4 levels
por: MacGlashan, Donald, et al.
Publicado: (2021)

Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies
por: Takahashi, Maika, et al.
Publicado: (2022)

Anti-SARS-CoV-2 spike IgG antibodies prevalence: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2023)

QUANTITATIVE STUDIES ON TUMOR ENHANCEMENT IN MICE : I. ENHANCEMENT OF SARCOMA I INDUCED BY IgM, IgG1, AND IgG2
por: Rubinstein, Pablo, et al.
Publicado: (1974)

Determination of IgG1 and IgG3 SARS-CoV-2 Spike Protein and Nucleocapsid Binding—Who Is Binding Who and Why?
por: Iles, Jason K., et al.
Publicado: (2022)

Specificity of fc receptors for IgG2a, IgG1/IgG2b, and IgE on rat macrophages
Publicado: (1981)

Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities
por: Orner, Erika P, et al.
Publicado: (2021)

ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2
por: Iwanaga, Naoki, et al.
Publicado: (2021)

SARS-CoV-2 Breakthrough Infections after Third Doses Boost IgG Specific Salivary and Blood Antibodies
por: Badano, María Noel, et al.
Publicado: (2023)

Association of dengue infection with anti-alpha-gal antibodies, IgM, IgG, IgG1, and IgG2
por: Olajiga, Olayinka M., et al.
Publicado: (2022)

Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2
por: Iwanaga, Naoki, et al.
Publicado: (2020)

One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG
por: Capetti, Amedeo F., et al.
Publicado: (2021)

Performance of the Roche/Snibe electrochemiluminescent anti-SARS-COV-2 spike assays compared to the Roche/Abbott IgG nucleocapsid and Abbott IgM spike assays
por: Lau, C.S., et al.
Publicado: (2021)

Characterization of adult patients with IgG subclass deficiency and subnormal IgG2
por: Barton, James C., et al.
Publicado: (2020)

Membranoproliferative glomerulonephritis with predominant IgG2 and IgG3 deposition in a patient with IgG4-related disease
por: Ueki, Kenji, et al.
Publicado: (2015)

Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein
por: Svilenov, Hristo L., et al.
Publicado: (2021)

Spike residue 403 affects binding of coronavirus spikes to human ACE2
por: Zech, Fabian, et al.
Publicado: (2021)

Usefulness and Limitations of Anti-S IgG Assay in Detecting Previous SARS-CoV-2 Breakthrough Infection in Fully Vaccinated Healthcare Workers
por: Spiteri, Gianluca, et al.
Publicado: (2022)

Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets
por: Bye, Alexander P., et al.
Publicado: (2021)

Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes
por: Voss, William N., et al.
Publicado: (2021)

IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection
por: Choudhary, Hari Ram, et al.
Publicado: (2021)

Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines
por: Alharbi, Naif Khalaf, et al.
Publicado: (2022)

Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months
por: Serwanga, Jennifer, et al.
Publicado: (2023)

Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19
por: Smith, Muneerah, et al.
Publicado: (2023)

A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction
por: Ejemel, Monir, et al.
Publicado: (2020)

A Multiplex Microsphere IgG Assay for SARS-CoV-2 Using ACE2-Mediated Inhibition as a Surrogate for Neutralization
por: Cameron, Andrew, et al.
Publicado: (2021)

Development of a high‐sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS‐CoV‐2 spike glycoprotein in serum and saliva
por: Faustini, Sian E., et al.
Publicado: (2021)

Variant-dependent oxidative and cytokine responses of human neutrophils to SARS-CoV-2 spike protein and anti-spike IgG1 antibodies
por: Almeida, Nathalie Bonatti Franco, et al.
Publicado: (2023)

IgG2a-producing variants of an IgG2b-producing mouse myeloma cell line
Publicado: (1978)

Cannot write session to /tmp/vufind_sessions/sess_i7d4mn7ijht170n99rgn8te27d